NCT00992160View on ClinicalTrials.gov

Vestipitant 28-day Tolerance Study

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Sleep Disorders
Interventions
DRUG

GW597599

GW597599 15mg tablet

DRUG

Placebo

Placebo to match GW597599 15mg tablet

Trial Locations (13)

10115

GSK Investigational Site, Berlin

10117

GSK Investigational Site, Berlin

10629

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

13125

GSK Investigational Site, Berlin

19053

GSK Investigational Site, Schwerin

19055

GSK Investigational Site, Schwerin

20246

GSK Investigational Site, Hamburg

20253

GSK Investigational Site, Hamburg

30159

GSK Investigational Site, Hanover

34131

GSK Investigational Site, Kassel

39112

GSK Investigational Site, Magdeburg

01307

GSK Investigational Site, Dresden

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00992160 - Vestipitant 28-day Tolerance Study | Biotech Hunter | Biotech Hunter